BlackRock
NKGN

BlackRock’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

BlackRock’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,854
Closed -$1.22K – 5545
2024
Q4 		$1.22K Hold
1,854
– – ﹤0.01% 5302
2024
Q3 		$701 Sell
1,854
-15,112
-89% -$13.4K ﹤0.01% 5147
2024
Q2 		$21.5K Buy
+16,966
New +$23.7K ﹤0.01% 5002

Other funds holding NKGN

DC
Diametric Capital Boston, Massachusetts $385M AUM 31.7% 1-Year Est. Return
UOC
University of Chicago Chicago, Illinois $323M AUM 14.1% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

BlackRock's NKGN Position: Q1 2025 in Review

BlackRock sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q1 2025, closing a stake of 1,854 shares — an estimated $1.22K sold.

BlackRock first reported a position in NKGN in Q2 2024 and held it in 3 quarters. The position peaked at $21.5K in Q2 2024. 3 funds tracked by Wall St. Rank hold NKGN as of Q1 2025.

  • BlackRock reported no remaining NKGen Biotech, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • BlackRock sold 1,854 NKGen Biotech, Inc. Common Stock shares in Q1 2025, an estimated $1.22K.
  • BlackRock first reported a position in NKGen Biotech, Inc. Common Stock in Q2 2024 and held it in 3 quarters.
  • BlackRock's NKGen Biotech, Inc. Common Stock position peaked at $21.5K in Q2 2024.
  • 3 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q1 2025.

Based on BlackRock's 13F filing for Q1 2025, filed 2 May 2025.